Survival rate and Factors Affecting on Survival of Colorectal Cancer Patients after Surgery at Roi Et Hospital

Main Article Content

Supattra Kumdinpitak

Abstract

Background and Objective: Colorectal cancer is a serious public health problem worldwide. It is a serious disease because patients are high risk to death. The colorectal cancer treatment by surgery can help to increase survival time of patients. The objective of this study was to study the survival rate and factors affecting on survival of colorectal cancer patients after surgery treatment at Roi Et Hospital.


Methods: this study was retrospective cohort study. All collection was retrieved from medical records of colorectal cancer patients after surgery treatment at Roi Et Hospital between January 1, 2015 and December 31, 2017. All patients were follow-up the vital status until death or end of the study, 31 October 2021. Data analyses were used descriptive statistics, Kaplan-Meier survival curve, Log rank test and Cox proportional hazard model. The statistically significant was set at p<0.05.


Results: of 354 patients with colorectal cancer with surgery treatment, the total follow-up time was 3,103 person-years, with 191 deaths, representing an incidence 61.55 per 1,000 person-years (95%CI: 53.12 to 70.92). The overall survival median survival time was 11.84 years (95%CI: 3.50 to 17.12), with cumulative 1year, 3-years, and 5-years survival rates respectively were 90.11%, 77.40 and 69.21.  The factors affecting on survival postoperative were palliative surgery (Adjusted HR= 5.15; 95%CI: 1.59-9.24), recurrence of disease (Adjusted HR= 4.89; 95%CI: 1.53-8.50) Histology grading were Poorly differentiated (Adjusted HR= 2.25; 95%CI: 1.04-4.81), Undifferentiated (Adjusted HR= 2.80; 95%CI: 3.07-8.52), Cancer Stage II (Adjusted HR = 8.01; 95%CI: 1.07-59.81), Stage III (Adjusted HR= 11.83; 95%CI: 2.98-59.91), Stage IV (Adjusted HR= 6.42; 95%CI: 2.41-46.15), cancer metastasis to liver (Adjusted HR= 3.14; 95%CI: 1.88-9.17), and lung (Adjusted HR = 2.67; 95%CI: 1.19-5.98).


Conclusion: Of 354 colorectal cancer patients after surgery treatment were found out that overall median survival time was 11.84 years. The factors affecting on survival of patients were palliative surgery, histology grading was poorly differentiated, undifferentiated, stage of cancer, and cancer metastasis to liver and lung.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Kumdinpitak S. Survival rate and Factors Affecting on Survival of Colorectal Cancer Patients after Surgery at Roi Et Hospital. SRIMEDJ [Internet]. 2022 Feb. 28 [cited 2023 Jan. 27];37(1):38-4. Available from: https://li01.tci-thaijo.org/index.php/SRIMEDJ/article/view/253040
Section
Original Articles

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209–49.
2. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 2021;127(16):3029–30.
3. McKeown RE. The Epidemiologic Transition: Changing Patterns of Mortality and Population Dynamics. Am J Lifestyle Med 2009;3(1):19S.
4. Omran AR. The Epidemiologic Transition: A Theory of the Epidemiology of Population Change. Milbank Q 2005;83(4):731.
5. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Lond Engl 2018;392(10159):1736–88.
6. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Lond Engl 2018;392(10159):1789–858.
7. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017;66(4):683–91.
8. Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology 2020;159(1):335-349.e15.
9. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70(1):7–30.
10. Rim SH, Seeff L, Ahmed F, King JB, Coughlin SS. Colorectal cancer incidence in the United States, 1999-2004 : an updated analysis of data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results Program. Cancer 2009;115(9):1967–76.
11. Thanikachalam K, Khan G. Colorectal Cancer and Nutrition. Nutrients 2019 14;11(1):E164.
12. Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology 2015;148(6):1244-1260.e16.
13. Akin H, Tözün N. Diet, microbiota, and colorectal cancer. J Clin Gastroenterol 2014;48 Suppl 1:S67-69.
14. Salibasic M, Pusina S, Bicakcic E, Pasic A, Gavric I, Kulovic E, et al. Colorectal Cancer Surgical Treatment, our Experience. Med Arch 2019;73(6):412–4.
15. Devoto L, Celentano V, Cohen R, Khan J, Chand M. Colorectal cancer surgery in the very elderly patient: a systematic review of laparoscopic versus open colorectal resection. Int J Colorectal Dis 2017;32(9):1237–42.
16. Dupré A, Jones RP, Diaz-Nieto R, Fenwick SW, Poston GJ, Malik HZ. Curative-intent treatment of recurrent colorectal liver metastases: A comparison between ablation and resection. Eur J Surg Oncol 2017;43(10):1901-1907
17. Zeng W-G, Zhou Z-X. Mini-invasive surgery for colorectal cancer. Chin J Cancer 2014;33(6):277–84.
18. Al-Hajeili M, Marshall JL, Smaglo BG. Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer. Oncol Williston Park N 2016;30(1):10–6.
19. Ohira G, Miyauchi H, Suzuki K, Nishimori T, Tohma T, Narushima K, et al. [Neoadjuvant chemotherapy for advanced colorectal cancer]. Gan To Kagaku Ryoho 2013;40(12):1626–8.
20. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen Y-J, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw JNCCN 2021;19(3):329–59.
21. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen Y-J, Ciombor KK, et al. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw 2020;18(7):806–15.
22. Benitez Majano S, Di Girolamo C, Rachet B, Maringe C, Guren MG, Glimelius B, et al. Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. Lancet Oncol 2019;20(1):74–87.
23. Aguiar Junior S, Oliveira MM de, Silva DRME, Mello CAL de, Calsavara VF, Curado MP. SURVIVAL OF PATIENTS WITH COLORECTAL CANCER IN A CANCER CENTER. Arq Gastroenterol 2020;57(2):172–7.
24. Lee SHF, Abdul Rahman H, Abidin N, Ong SK, Leong E, Naing L. Survival of colorectal cancer patients in Brunei Darussalam: comparison between 2002-09 and 2010-17. BMC Cancer 2021;21(1):477.
25. Schmoor C, Sauerbrei W, Schumacher M. Sample size considerations for the evaluation of prognostic factors in survival analysis. Stat Med 2000;19(4):441–52.
26. Percy C, Holten V van, Muir CS, Organization WH. International classification of diseases for oncology [Internet]. World Health Organization; 1990 [cited 2021 Nov 4]. Available from: https://apps.who.int/iris/handle/10665/39441
27. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424.
28. Coleman M, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011;377(9760):127–38.
29. Yuan Y, Li M-D, Hu H-G, Dong C-X, Chen J-Q, Li X-F, et al. Prognostic and survival analysis of 837 Chinese colorectal cancer patients. World J Gastroenterol WJG 2013;19(17):2650–9.
30. Yeole BB, Sunny L, Swaminathan R, Sankaranarayanan R, Parkin DM. Population-based survival from colorectal cancer in Mumbai, (Bombay) India. Eur J Cancer Oxf Engl 2001;37(11):1402–8.
31. Shiono S, Ishii G, Nagai K, Yoshida J, Nishimura M, Murata Y, et al. Histopathologic prognostic factors in resected colorectal lung metastases. Ann Thorac Surg 2005;79(1):278–82
32. Ghazali AK, Musa KI, Naing NN, Mahmood Z. Prognostic factors in patients with colorectal cancer at Hospital Universiti Sains Malaysia. Asian J Surg 2010;33(3):127–33.
33. Maajani K, Khodadost M, Fattahi A, Shahrestanaki E, Pirouzi A, Khalili F, et al. Survival Rate of Colorectal Cancer in Iran: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev 2019;20(1):13–21.
34. Gray RT, Coleman HG, Hughes C, Murray LJ, Cardwell CR. Statin use and survival in colorectal cancer: Results from a population-based cohort study and an updated systematic review and meta-analysis. Cancer Epidemiol 2016;45:71–81.
35. Wu W, Yang J, Li D, Huang Q, Zhao F, Feng X, et al. Competitive Risk Analysis of Prognosis in Patients With Cecum Cancer: A Population-Based Study. Cancer Control J Moffitt Cancer Cent 2021;28:1073274821989316.
36. Iizasa T, Suzuki M, Yoshida S, Motohashi S, Yasufuku K, Iyoda A, et al. Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg 2006;82(1):254–60.
37. Inoue M, Ohta M, Iuchi K, Matsumura A, Ideguchi K, Yasumitsu T, et al. Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2004;78(1):238–44.
38. Hisada H, Takahashi Y, Kubota M, Shimura H, Itobayashi E, Shimura K, et al. Clinical and therapeutic features and prognostic factors of metastatic colorectal cancer over age 80: a retrospective study. BMC Gastroenterol 2021;21(1):199.
39. Shuayb M, Mehedi Hasan M, Hoque MR, Mushtaq Hussain Q, Begum R, Reza MS. Survival and prognostic association in stage IV colorectal cancer patients treated with chemotherapy in Bangladesh. Jpn J Clin Oncol 2021;51(4):552–9.
40. Croft B, Reed M, Patrick C, Kovacevich N, Voutsadakis IA. Diabetes, Obesity, and the Metabolic Syndrome as Prognostic Factors in Stages I to III Colorectal Cancer Patients. J Gastrointest Cancer 2019;50(2):221–9.
41. Reed M, Patrick C, Croft B, Walde N, Voutsadakis IA. The metabolic syndrome and its components as prognostic factors in metastatic colorectal cancer. Indian J Gastroenterol Off J Indian Soc Gastroenterol 2019;38(1):15–22.